Search

Your search keyword '"Scaringi, Claudia"' showing total 196 results
Start Over Author "Scaringi, Claudia"
196 results on '"Scaringi, Claudia"'

6. Imaging in Neuro-Oncology

Author

Minniti, Giuseppe, Romano, Andrea, Scaringi, Claudia, Bozzao, Alessandro, Bartolo, Michelangelo, editor, Soffietti, Riccardo, editor, and Klein, Martin, editor

Published
2019
Full Text
View/download PDF

7. Fractionated Radiosurgery

Author

Minniti, Giuseppe, Scaringi, Claudia, Trifiletti, Daniel M., editor, Chao, Samuel T., editor, Sahgal, Arjun, editor, and Sheehan, Jason P., editor

Published
2019
Full Text
View/download PDF

11. 2215: Interobserver contouring variability in postoperative stereotactic radiotherapy of brain metastases

Author

Paoli, Camilla Delli, Gregucci, Fabiana, Bartoli, Francesco Beghella, Desideri, Isacco, Guerini, Andrea, Diletto, Barbara, Bonzano, Elisabetta, Viola, Anna, Scaringi, Claudia, Clerici, Elena, Dall'Oglio, Stefano, Bignardi, Mario, Marini, Beatrice, Amelio, Dante, Fontana, Antonella, Marchese, Rita, Molinari, Alessandro, Berretta, Laura, Di Franco, Rossella, Piperno, Gaia, Giannelli, Flavio, Cantarella, Martina, Navarria, Piera, Scoccianti, Silvia, and Chiesa, Silvia

Published
2024
Full Text
View/download PDF

15. Radiotherapy and Radiosurgery

Author

Minniti, Giuseppe, Scaringi, Claudia, Cappabianca, Paolo, editor, Cavallo, Luigi Maria, editor, de Divitiis, Oreste, editor, and Esposito, Felice, editor

Published
2016
Full Text
View/download PDF

18. Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS)

Author

Mercadante, Sebastiano, Marchetti, Paolo, Cuomo, Arturo, Caraceni, Augusto, Mediati, Rocco Domenico, Mammucari, Massimo, Natoli, Silvia, Lazzari, Marzia, Dauri, Mario, Airoldi, Mario, Azzarello, Giuseppe, Bandera, Mauro, Blasi, Livio, Cartenì, Giacomo, Chiurazzi, Bruno, Costanzo, Benedetta Veruska Pierpaola, Degiovanni, Daniela, Fusco, Flavio, Guardamagna, Vittorio, Iaffaioli, Vincenzo, Liguori, Simeone, Lorusso, Vito, Mameli, Sergio, Mattioli, Rodolfo, Mazzei, Teresita, Melotti, Rita Maria, Menardo, Valentino, Miotti, Danilo, Moroso, Stefano, De Santis, Stefano, Orsetti, Remo, Papa, Alfonso, Ricci, Sergio, Sabato, Alessandro Fabrizio, Scelzi, Elvira, Sofia, Michele, Tonini, Giuseppe, Aielli, Federica, Valle, Alessandro, Caruselli, Amanda, Prestia, Giovanna, Giusti, Raffaele, Costanzi, Andrea, Angelini, Silvia, Iacono, Daniela, Mazzuca, Federica, Carnevale, Alessia, Bonome, Paolo, Nicosia, Luca, Scaringi, Claudia, Montalto, Adelaide, Russo, Gennaro, Forte, Cira Antonietta, Esposito, Gennaro, Bracchi, Paola, Zecca, Ernesto, Campa, Tiziana, Grecchi, Silvia, Pigni, Alessandra, Sammaro, Annunziata, Dodaro, Lucia, Ballerini, Giovanna, Vellucci, Renato, Caldarulo, Clarissa, Palombo, Elisa, Diviza, Marco, Gianfelice, Valentina, Silvestri, Claudia, Finocchi, Simona, Contu, Viviana, Fora, Gianluca, Pedani, Fulvia, Icardi, Massimiliano, Bellini, Elisa, Celano, Alfredo, Berardo, Roberto, Ostellino, Oliviero, Sartori, Kayta, Demartini, Paola, Scroccaro, Raffaella, Boscolo, Giorgia, Sartori, Donata, Rosetti, Francesco, Artioli, Grazia, Borgato, Lucia, Bertoldero, Giovanni, Veronese, Barbara, Vallini, Ilaria, Tuzi, Alessandro, Bolzacchini, Elena, Pinotti, Graziella, Alù, Massimiliano, Usset, Antonella, Arcuri, Carmela, Laudani, Agata, Pepe, Alessio, Scagliarini, Sarah, Sgarlata, Massimiliano Savio Maria, Raimondi, Massimo, Valenti, Salvatore Maria Giovanni, Bucceri, Alberto, Kasa, Alma, Budel, Paola, Caramellino, Anna, Ballarino, Paola, Donelli, Emanuela, Silvestro, Stefania, Tonetti, Rossella, Bozzoni, Samuela, Cocquio, Angela, Romano, Carmela, Nappi, Anna, Silvestro, Lucrezia, De Divitiis, Chiara, Ghidoni, Silvia, Cortinovis, Rosalba, Marchesi, Roberta, Fortis, Michele, Palermo, Loredana, Pisanu, Giovanni Maria, Carboni, Maura, Meloni, Francesca, Barillari, Daniele, Imperatori, Luca, Grilli, Gianni, Laici, Gianluca, Diacciati, Sara, Petreni, Paolo, Samolsky Dekel, Boaz, Marsigli, Federica, Manfreda, Miriam, Ghedini, Silvia, Bruno, Emanuela, Salvini, Emanuele, Gerboni, Davide, Saulle, Serena, Carella, Roberta, Pascoletti, Gaetano, Bolzonello, Silvia, Bonotto, Marta, Ellero, Silvia, Fasola, Gianpiero, Ongaro, Elena, Borghesi, Cristina, Germani, Lucia, De Ruvo, Edoardo, Marchetti, Federica, Pasquale, Milena, Masu, Lucia, Tammaro, Dario, Saracco, Elisabetta, Di Dato, Maria Teresa, Ferrara, Maurizio, Pironti, Andrea, Buonavolontà, Pietro, Ginocchi, Laura, Musettini, Gianna, Antonuzzo, Andrea, Caparello, Chiara, Lucchesi, Maurizio, Farnesi, Azzurra, Zampieri, Mari, Pisciotta, Manuela, Fioroni, Iacopo, Ratta, Raffaele, Cursano, Maria Concetta, Santini, Daniele, Potestà, Cinzia, Gallo, Gloria, Saber, Benhaz, and On behalf of the IOPS MS study group

Published
2017
Full Text
View/download PDF

26. Quality of life and sexual functioning among endometrial cancer patients treated with one week adjuvant high-dose-rate vaginal brachytherapy schedule

Author

Facondo, Giuseppe, primary, Vullo, Gianluca, additional, De Sanctis, Vitaliana, additional, Vitiello, Cecilia, additional, Nieddu, Luciano, additional, Alfò, Marco, additional, Scaringi, Claudia, additional, De Felice, Francesca, additional, Rotondi, Margherita, additional, De Giacomo, Flavia, additional, Ruscito, Ilary, additional, Valeriani, Maurizio, additional, and Falchetto Osti, Mattia, additional

Published
2022
Full Text
View/download PDF

33. Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET

Author

Cicone, Francesco, primary, Carideo, Luciano, additional, Scaringi, Claudia, additional, Romano, Andrea, additional, Mamede, Marcelo, additional, Papa, Annalisa, additional, Tofani, Anna, additional, Cascini, Giuseppe Lucio, additional, Bozzao, Alessandro, additional, Scopinaro, Francesco, additional, and Minniti, Giuseppe, additional

Published
2020
Full Text
View/download PDF

34. Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)

Author

Roila, Fausto, Fumi, Guglielmo, Ruggeri, Benedetta, Antonuzzo, Andrea, Ripamonti, Carla, Fatigoni, Sonia, Cavanna, Luigi, Gori, Stefania, Fabi, Alessandra, Marzano, Nicola, Graiff, Claudio, De Sanctis, Vitaliana, Mirabile, Aurora, Serpentini, Samantha, Bocci, Chiara, Pino, Maria Simona, Cilenti, Giuseppina, Verusio, Claudio, Ballatori, Enzo, Sbrana, Andrea, Musettini, Gianna, Farnesi, Azzurra, Spina, Francesco, Matteucci, Paola, Bossi, Paolo, Minenza, Elisa, Di&nbsp, Nunzio, Camilla, Orlandi, Elena, Biasini, MARIA CLAUDIA, Inno, Alessandro, Turazza, Monica, Marchetti, Fabiana, Pellegrini, Domenica, Gasparro, Simona, Alesini, Daniele, De&nbsp, Feudis, Rossana, Gasparre, Teresa, Altieri, Michele, Cretella, Elisabetta, Marabese, Alessandro, Valeriani, Maurizio, Scaringi, Claudia, Artale, Salvatore, Barbarini, Lucia, Capovilla, Eleonora, Tessarin, Silvia, Ivaldi, Giovanni Battista, Meaglia, Ilaria, Maiello, Evaristo, Parati, Chiara, Cinieri, Saverio, Coltelli, Luigi, Ribecco, Angela S., Romagnoli, Emanuela, Ardizzoia, Antonio, Tralongo, Paolo, Falzetta, Amalia, Bandieri, Elena, and Danova, Marco

Subjects
Adult, Male, medicine.medical_specialty, Cancer-related fatigue, Cross-sectional study, Anemia, Physical exercise, Anxiety, Characteristics of fatigue, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Quality of life, Internal medicine, Neoplasms, Surveys and Questionnaires, medicine, Prevalence, Humans, 030212 general & internal medicine, Exercise, Depression (differential diagnoses), Fatigue, Aged, Aged, 80 and over, business.industry, Depression, Cancer Pain, Middle Aged, medicine.disease, Exercise Therapy, Non-pharmacological treatment, Mood, Cross-Sectional Studies, Italy, cancer-related fatigue, characteristics of fatigue, non-pharmacological treatment, pharmacological treatment, oncology, 030220 oncology & carcinogenesis, Pharmacological treatment, Quality of Life, Female, medicine.symptom, business
Abstract

Fatigue is one of the most distressing symptoms of cancer patients. Its characteristics and impact on quality of life have not been fully explored and treatment of cancer-related fatigue in Italian oncological centers has not been codified. A cross-sectional study was carried out on all patients attending for any reason the 24 participating centers in two non-consecutive days. Patients with fatigue filled out the Brief Fatigue Inventory (BFI) questionnaire and reported any pharmacological or non-pharmacological treatment for fatigue. From October 2014 to May 2015, 1394 cancer patients agreed to participate in the study. Fatigue was referred by 866 (62.1%) of patients; its duration was > 4 months in 441 patients (50.9%). In the investigators’ opinion, the most important (probable or almost sure) determinants of fatigue were reduced physical activity (271 patients), anxiety (149), pain (131), insomnia (125), anemia (123), and depression (123). Fatigue of moderate/severe intensity was reported by 43%/29.2% of patients, while usual fatigue in the last 24 h by 45%/33.1%, and the worst fatigue in the last 24 h by 33%/54.8%, respectively. Concerning the impact on quality of life, fatigue interfered moderately/severely with general activity in 30.8%/38.6% of patients, with mood in 26.1%/32.8%, with the ability to work in 27.9%/35.6%, with normal work in 26.7%/38.9%, with relationships with others in 21%/23.4% and with the ability to amuse themselves in 22.2%/33.1%. Only 117/866 patients (13.5%) received a pharmacological treatment represented by a corticosteroid in 101 patients (86.3%) while 188 patients (21.7%) received a non-pharmacological treatment such as physical exercise (120 patients, 63.8%) and various alimentary supplements (52 patients, 27.6%). Cancer-related fatigue is frequently reported by oncological patients; its intensity and impact on quality of life is relevant.

Published
2019

35. Radiation techniques for acromegaly

Author

Minniti Giuseppe, Scaringi Claudia, and Enrici Riccardo

Subjects
acromegaly, fractionated stereotactic radiotherapy, radiosurgery, toxicity, GH-secreting pituitary tumors, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Radiotherapy (RT) remains an effective treatment in patients with acromegaly refractory to medical and/or surgical interventions, with durable tumor control and biochemical remission; however, there are still concerns about delayed biochemical effect and potential late toxicity of radiation treatment, especially high rates of hypopituitarism. Stereotactic radiotherapy has been developed as a more accurate technique of irradiation with more precise tumour localization and consequently a reduction in the volume of normal tissue, particularly the brain, irradiated to high radiation doses. Radiation can be delivered in a single fraction by stereotactic radiosurgery (SRS) or as fractionated stereotactic radiotherapy (FSRT) in which smaller doses are delivered over 5-6 weeks in 25-30 treatments. A review of the recent literature suggests that pituitary irradiation is an effective treatment for acromegaly. Stereotactic techniques for GH-secreting pituitary tumors are discussed with the aim to define the efficacy and potential adverse effects of each of these techniques.

Published
2011
Full Text
View/download PDF

36. Frameless linac-based stereotactic radiosurgery (SRS) for brain metastases: analysis of patient repositioning using a mask fixation system and clinical outcomes

Author

Minniti Giuseppe, Scaringi Claudia, Clarke Enrico, Valeriani Maurizio, Osti Mattia, and Enrici Riccardo

Subjects
stereotactic radiosurgery, positioning reproducibility, isocenter verification, brain metastases, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Purpose To assess the accuracy of patient repositioning and clinical outcomes of frameless stereotactic radiosurgery (SRS) for brain metastases using a stereotactic mask fixation system. Patients and Methods One hundred two patients treated consecutively with frameless SRS as primary treatment at University of Rome Sapienza Sant'Andrea Hospital between October 2008 and April 2010 and followed prospectively were involved in the study. A commercial stereotactic mask fixation system (BrainLab) was used for patient immobilization. A computerized tomography (CT) scan obtained immediately before SRS was used to evaluate the accuracy of patient repositioning in the mask by comparing the isocenter position to the isocenter position established in the planning CT. Deviations of isocenter coordinates in each direction and 3D displacement were calculated. Overall survival, brain control, and local control were estimated using the Kaplan-Meier method calculated from the time of SRS. Results The mean measured isocenter displacements were 0.12 mm (SD 0.35 mm) in the lateral direction, 0.2 mm (SD 0.4 mm) in the anteroposterior, and 0.4 mm (SD 0.6 mm) in craniocaudal direction. The maximum displacement of 2.1 mm was seen in craniocaudal direction. The mean 3D displacement was 0.5 mm (SD 0.7 mm), being maximum 2.9 mm. The median survival was 15.5 months, and 1-year and 2-year survival rates were 58% and 24%, respectively. Nine patients recurred locally after SRS, with 1-year and 2-year local control rates of 91% and 82%, respectively. Stable extracranial disease (P = 0.001) and KPS > 70 (P = 0.01) were independent predictors of survival. Conclusions Frameless SRS is an effective treatment in the management of patients with brain metastases. The presented non-invasive mask-based fixation stereotactic system is associated with a high degree of patient repositioning accuracy; however, a careful evaluation is essential since occasional errors up to 3 mm may occur.

Published
2011
Full Text
View/download PDF

42. Single-Fraction Versus Multifraction (3 × 9 Gy) Stereotactic Radiosurgery for Large (2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis

Author

Minniti, Giuseppe, Scaringi, Claudia, Paolini, Sergio, Lanzetta, Gaetano, Romano, Andrea, Cicone, Francesco, Osti, Mattia Falchetto, Enrici, Riccardo Maurizi, Esposito, Vincenzo, and MAURIZI ENRICI, Riccardo

Subjects
Adult, Male, Risk, Cancer Research, medicine.medical_treatment, Radiation induced, Brain necrosis, Radiosurgery, 03 medical and health sciences, Necrosis, 0302 clinical medicine, Nuclear Medicine and Imaging, parasitic diseases, Medicine, Humans, Radiology, Nuclear Medicine and imaging, Cumulative incidence, In patient, Propensity Score, Radiation Injuries, Aged, Aged, 80 and over, Radiation, Medicine (all), Oncology, Radiology, Nuclear Medicine and Imaging, business.industry, Brain Neoplasms, Dose fractionation, Brain, Middle Aged, Single fraction, 3. Good health, 030220 oncology & carcinogenesis, Propensity score matching, Female, Dose Fractionation, Radiation, business, Nuclear medicine, Radiology, 030217 neurology & neurosurgery
Abstract

Purpose To investigate the local control and radiation-induced brain necrosis in patients with brain metastases >2 cm in size who received single-fraction or multifraction stereotactic radiosurgery (SRS); factors associated with clinical outcomes and the development of brain radionecrosis were assessed. Methods and Materials Two hundred eighty-nine consecutive patients with brain metastases >2.0 cm who received SRS as primary treatment at Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy, were analyzed. Cumulative incidence analysis was used to compare local control and radiation-induced brain necrosis between groups from the time of SRS. To achieve a balanced distribution of baseline covariates between treatment groups, a propensity score analysis was used. Results The 1-year cumulative local control rates were 77% in the single-fraction SRS (SF-SRS) group and 91% in the multifraction SRS (MF-SRS) group ( P =.01). Recurrences occurred in 25 and 11 patients who received SF-SRS or MF-SRS ( P =.03), respectively. Thirty-one patients (20%) undergoing SF-SRS and 11 (8%) subjected to MF-SRS experienced brain radionecrosis ( P =.004); the 1-year cumulative incidence rate of radionecrosis was 18% and 9% ( P =.01), respectively. Significant differences between the 2 groups in terms of local control and risk of radionecrosis were maintained after propensity score adjustment. Conclusions Multifraction SRS at a dose of 27 Gy in 3 daily fractions seems to be an effective treatment modality for large brain metastases, associated with better local control and a reduced risk of radiation-induced radionecrosis as compared with SF-SRS.

Published
2015

43. 18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.

Author

Cicone, Francesco, Carideo, Luciano, Scaringi, Claudia, Arcella, Antonietta, Giangaspero, Felice, Scopinaro, Francesco, and Minniti, Giuseppe

Abstract

Objective: The role of amino acid positron emission tomography (PET) in glioma grading and outcome prognostication has not yet been well established. This is particularly true in the context of the new WHO 2016 classification, which introduced a definition of glioma subtypes primarily based on molecular fingerprints. The aim of the present study was to correlate 3,4‑dihydroxy‑6‑[18F]‑fluoro-L‑phenylalanine (F-DOPA) uptake parameters with IDH mutation, 1p/19q status, and survival outcomes in patients with glioma.Methods: The study population consisted of 33 patients (17 M/16 F, mean age: 46 ± 13 years) who underwent F-DOPA PET/CT for the evaluation of tumor extent before the start of chemo or radiotherapy. The presence of IDH mutation and 1p/19q status was assessed in all the cases. Tumor volume and semiquantitative uptake parameters, namely SUVmax, tumor-to-normal brain ratio and tumor-to-normal striatum ratio, were calculated for each tumor. Imaging-derived parameters were compared between patients stratified according to molecular fingerprints, using parametric or non-parametric tests, where appropriate. The Kaplan-Meier method was used to assess differences of overall survival (OS) and progression-free survival (PFS) between groups. PET parameters were also tested as prognostic factors in univariate Cox survival regression models.Results: There were 12 IDH-wild-type and 21 IDH-mutant patients. Stratification according to 1p/19q co-deletion resulted in 20 non-co-deleted and 13 co-deleted patients. Median follow-up time from PET/CT exam was 30.5 months (range 3.5-74 months). Semiquantitative uptake parameters did correlate neither with IDH mutation nor with 1p/19q status. Uptake was similar in low-grade and high-grade tumors, respectively. In addition, F-DOPA uptake parameters, macroscopic tumor volume, or tumor grade did not stratify OS, while a correlation between SUVmax and PFS was shown in the subgroup of astrocytomas. On the other hand, IDH mutation status and presence of 1p/19q co-deletion had a significant impact on survival outcomes. The prognostic value of IDH mutation status was also confirmed in the subgroup of patients with astrocytic tumors.Conclusions: F-DOPA uptake parameters do not correlate with tumor molecular and histological characteristics. The predictive value of PET-derived parameters on outcomes of survival is limited. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

46. Single-Fraction Versus Multifraction (3 × 9 Gy) Stereotactic Radiosurgery for Large (>2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis

Author

Minniti, Giuseppe, primary, Scaringi, Claudia, additional, Paolini, Sergio, additional, Lanzetta, Gaetano, additional, Romano, Andrea, additional, Cicone, Francesco, additional, Osti, Mattia, additional, Enrici, Riccardo Maurizi, additional, and Esposito, Vincenzo, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results